Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented an innovative polymer delivery system called Invisicare® and formulated over forty topical skin products, which it out-licenses globally. The company targets the $80 billion global skincare and dermatology market and the $30 billion global over-the-counter market, as well as other healthcare and consumer goods markets. Skinvisible is also exploring opportunities in large…
Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented an innovative polymer delivery system called Invisicare® and formulated over forty topical skin products, which it out-licenses globally. The company targets the $80 billion global skincare and dermatology market and the $30 billion global over-the-counter market, as well as other healthcare and consumer goods markets. Skinvisible is also exploring opportunities in large medical markets outside dermatology, such as obesity, where topical or transdermal solutions could serve as viable alternatives. With research and development complete on forty products and numerous patents issued, the company is focused on monetizing its investment through out-licensing its patented prescription and over-the-counter products featuring Invisicare to established manufacturers and marketers internationally.
Skinvisible generates revenue primarily through licensing its topical prescription and over-the-counter products enhanced with Invisicare to pharmaceutical and consumer goods companies worldwide for upfront fees and ongoing royalties. The company also earns revenue through co-development services, assisting pharmaceutical clients in the early development of optimal formulations that they then advance into clinical testing. Additionally, Skinvisible provides life cycle management solutions by reformulating products coming off patent with new Invisicare-based patents and product benefits, offering line extensions to global pharmaceutical companies facing revenue loss from expiring drug patents.
The company operates through the following segments:
- Licensing: This segment involves developing topical prescription and over-the-counter products enhanced with Invisicare® for out-licensing to pharmaceutical and consumer goods companies globally. Skinvisible receives upfront fees and ongoing royalties from these licensing agreements. The segment includes the trademarked technology Invisicare® and licensed products such as DermSafe and QRX003.
- Co-Development: This segment focuses on assisting pharmaceutical clients in the early development of optimal formulations using Invisicare® technology, which the clients then take forward into clinical testing. Skinvisible provides formulation expertise and delivery system integration to enhance product performance. The segment leverages the Invisicare® polymer delivery system as a key asset in collaborative development efforts.
- Life Cycle Management: This segment provides cost-effective solutions to global pharmaceutical companies by reformulating products coming off patent with new Invisicare® patents and updated product benefits. Skinvisible creates line extensions that offer extended market exclusivity and differentiated products. The segment utilizes the Invisicare® delivery technology to enhance existing products with improved durability, efficacy, and consumer appeal.
Skinvisible operates in a niche within the pharmaceutical and skincare industries, competing with larger firms that have greater resources, longer operating histories, and stronger brand recognition. The company's competitive advantage lies in its patented Invisicare® polymer delivery system, which offers unique benefits such as extended skin adhesion, controlled release of active ingredients, reduced irritation, and enhanced moisture retention without occluding the skin. These scientifically validated properties differentiate Skinvisible’s offerings from conventional delivery systems and support its marketing and licensing efforts.
Skinvisible serves pharmaceutical and consumer goods companies globally that seek to enhance their product portfolios with advanced delivery technologies. Specific customers mentioned in the filing include Quoin Pharmaceuticals, Inc. and Ovation Science Inc., which have licensed Skinvisible’s Invisicare® technology for products such as QRX003 and DermSafe. The company’s customer base consists of businesses looking to license, co-develop, or manage the life cycle of topical and transdermal products using Skinvisible’s proprietary technology.